1. Introduction {#sec1-1}
===============

Tardive dyskinesia (TD) can occur in up to 20% of schizophrenia patients receiving long-term antipsychotics (APs)^\[[@ref1]\]^, and is associated with considerable personal suffering and social and physical disabilities.^\[[@ref3]\]^ TD is characterized by abnormal and involuntary movements (such as choreiform, athetoid and rhythmic) on orofacial, extremities, or even truncal region.^\[[@ref5]\]^ Numerous medications for TD have been examined, but there have been no well-proven treatments.^\[[@ref6]\]^

The pathophysiology of APs induced TD remains controversial. Free radicals associated with low brain-derived neurotrophic factor (BDNF) is probably involved in the process.^\[[@ref2],[@ref7],[@ref8]\]^ Several antioxidants, based on the free radical hypothesis of TD, have been studied for the therapeutic effects of TD, such as melatonin^\[[@ref6],[@ref9]\]^, vitamin B~6~^\[[@ref12],[@ref13]\]^, vitamin E^\[[@ref14],[@ref15]\]^, *Ginkgo biloba* (EGb)^\[[@ref4]\]^ and piracetam.^\[[@ref16],[@ref17]\]^

Melatonin (N-acetyl-5-methoxytryptamine), a neurohormone that is secreted by the pineal gland, is a naturally occurring potent antioxidant in the brain.^\[[@ref5],[@ref18]\]^ Animal model studies^\[[@ref19]\]^ suggested that melatonin is efficacious in the improvement of abnormal movements. Some randomized controlled trials (RCTs)^\[[@ref6],[@ref9]\]^ have examined the efficacy and safety of adjunctive melatonin for schizophrenia patients with TD, but results are inconsistent.

One review^\[[@ref5]\]^ which examined the efficacy of melatonin for schizophrenia patients with TD based on only two RCTs^\[[@ref10],[@ref11]\]^ used qualitative analysis without adequate assessment of study quality. Hence, the objective of this RCT meta-analysis was to systematically assess the efficacy and safety of adjunctive melatonin therapy for TD in schizophrenia using both English and Chinese databases since the latter is not widely known internationally.

2. Methods {#sec1-2}
==========

2.1 Search Strategy and Selection Criteria {#sec2-1}
------------------------------------------

Two authors (WZ and D-BC) independently and systematically searched English (PubMed, PsycINFO, Embase, Cochrane Library databases) and Chinese databases (Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), SINOMED), with each database from their inception until June 8, 2017, using the following search terms: (Tardive Dyskinesia OR Dyskinesia\*, Tardive OR Dyskinesias, Tardive OR Dystonias, Tardive) AND (Mélatonine OR Melatonin). Reference lists of all identified RCTs and relevant review articles^\[[@ref5]\]^ for additional studies were also hand-searched.

The following selection criteria were presented using the PICOS acronym: Participants: adult schizophrenia patients with TD (≥18 years) by any diagnostic criteria. Intervention: melatonin combined with APs. Comparison: APs combined with placebo or APs monotherapy. Outcomes: the primary outcome measure was the severity of TD symptoms at endpoint assessment measured by the Abnormal Involuntary Movement Scale (AIMS).^\[[@ref22],[@ref23]\]^ Key secondary outcomes were cognitive function, adverse drug reactions (ADRs), and discontinuation rate. Study design: RCTs with meta-analyzable data.

The literature from the above databases was screened by two independent authors (WZ and D-BC) using EndNote X6 software. [Figure 1](#fig001){ref-type="fig"} presents the literature screening process. Any disagreement during this process was resolved through a discussion.

2.2 Data extraction {#sec2-2}
-------------------

Two authors (D-BC and X-HY) independently and systematically extracted data and conducted quality assessment of included RCTs. Any disagreement was resolved through a discussion and consensus. Data were extracted into standard forms. Whenever data were missing for the meta-analysis, first or correspondence authors were contacted by email or telephone for additional information if possible.

2.3 Statistical methods {#sec2-3}
-----------------------

According to the guidelines from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement^\[[@ref24]\]^, we used the Review Manager (RevMan) Version 5.3 (<http://tech.cochrane.org/revman/>) to perform this meta-analysis in cases that continuous data followed normal distribution (i.e., the mean \> 2 times the standard deviation when the minimum value was 0). A sensitivity analysis was conducted by excluding skewed data. For meta-analytic pooling of continuous and dichotomous outcomes, the Inverse-Variance method and Mantel-Haenszel test were used to present weighted mean differences (WMDs) and risk ratios (RRs) with their 95% confidence intervals (CIs), respectively. Intention-to-treat (ITT) data over observed cases (OC) data were preferred when both were provided. In order to compensate for study heterogeneity, the random effect model was used in all meta-analyzable outcomes.^\[[@ref25]\]^ Heterogeneity was presented by I-squared statistic. When I-square was greater than 50%, sensitivity, subgroup and meta-regression analyses were conducted to detect the sources of heterogeneity. Furthermore, data of primary outcome were entered into a funnel plots or analyzed using Egger's test^\[[@ref26]\]^ to test Publication bias. All analyses were two tailed, with significance level set at 0.05.

2.4 Assessment of study quality {#sec2-4}
-------------------------------

The methodological quality of the RCTs was assessed using the Cochrane risk of bias assessment tool^\[[@ref27]\]^ with 7 dimension as follows: (a) random sequence generation; (b) allocation concealment; (c) blinding of the subjects and the treatment providers; (d) blinding of the result evaluators); (e) incomplete results data; (f) selective reporting; (g) other potential risks. Furthermore, the Jadad scale was used to assess study quality.^\[[@ref28]\]^ High and low quality of included RCTs were defined as Jadad score ≥3 and \<3, respectively. In addition, the overall evidence quality of all meta-analyzable outcomes was rated as "very low ", "low", "moderate " and "high" by two independent authors (WZ and D-BC) using the grading of recommendations assessment, development, and evaluation (GRADE) system.^\[[@ref29],[@ref30]\]^

3. Results {#sec1-3}
==========

3.1 Results of the search {#sec2-5}
-------------------------

[Figure 1](#fig001){ref-type="fig"} presents a flow chart of article selection from English (n=206) and Chinese databases (n=10). Finally, 4 RCTs (Castro 2011; Shamir 2000; Shamir 2001; Zhu 2010) were eligible and included for the meta-analysis ([Figure 1](#fig001){ref-type="fig"}).

3.2 The characteristics of included studies {#sec2-6}
-------------------------------------------

Three double-blinded trials (Castro 2011; Shamir 2000; Shamir 2001) and one rater masked trial (Zhu 2010) compared adjunctive melatonin (n=67) and control groups (n=63) ([Table 1](#table001){ref-type="table"}). The weighted mean treatment duration was 9.8 weeks (range=4-12 weeks) ([Table 1](#table001){ref-type="table"}). Of the 4 RCTs, two RCTs (Shamir 2000; Shamir 2001) were conducted in Israel (n=41), one in China (Zhu 2010, n=76) and one in Venezuela (Castro 2011, n=13), respectively. While 24 patients in Shamir 2001 were eligible, 22 patients were described and analyzed because 2 patients were discharged from the hospital before initiation of the study.

3.3 Patient characteristics {#sec2-7}
---------------------------

The weighted mean age was 61.3 years (range =57.6-74.0 years) ([Table 1](#table001){ref-type="table"}), the percentage of males was 41.54% (range=34.2%-69.2%), and the weighted mean illness duration in 3 RCTs (Castro 2011; Shamir 2000; Shamir 2001) with available data was 28.6 years (range=24.8-31.3 years). The RCTs (n=130) were conducted in inpatient (n=119, 91.5%) and outpatient (n=3, 2.3%) and rehabilitation institution settings (n=8, 6.2%).

3.4 Treatment characteristics {#sec2-8}
-----------------------------

The weighted mean dosage of melatonin dosage was 9.2 mg/day (range=2.0-20.0 mg/day). One RCT (Zhu 2010) did not report details of APs use, but the remaining RCTs (Castro 2011; Shamir 2000; Shamir 2001) reported using a range of APs including levopromazine, haloperidol, clozapine, aripiprazole, olanzapine, quetiapine, risperidone, perphenazine, zuclopenthixol and chlorpromazine. Furthermore, the mean dosage of mixed APs in the 3 RCTs with available data was 262.3 mg/day in chlorpromazine dose equivalents. Only one RCT (Castro 2011) reported the study funding sources.

3.5 Risk of bias {#sec2-9}
----------------

One RCT (Shamir 2001) mentioned "random" assignment with specific description, 3 RCTs (Castro 2011; Shamir 2000; Shamir 2001) used double blind and 1 RCT (Zhu 2010) used masked assessors ([Table 2](#table002){ref-type="table"}). Two RCTs (Shamir 2000; Shamir 2001) were rated as low risk regarding the allocation concealment methods and the potential for selective reporting. Incomplete outcome data addressed and other sources of bias (e.g., drug company sponsorship) were rated as low risk and unclear in all included RCTs.

3.6 Jadad scale {#sec2-10}
---------------

The weighted mean Jadad total score of the 4 RCTs was 2.4 (range=1-5). While one RCT (Zhu 2010) was classified as low quality, 75% RCTs (n=3) (Castro 2011; Shamir 2000; Shamir 2001) were rated as high quality.

3.7 Primary outcome {#sec2-11}
-------------------

The improvement of TD symptoms: there were differences between the two groups in terms of the AIMS total score (4 RCTs) at the treatment endpoint. Adjunctive melatonin was superior in reducing the severity of TD symptoms (4 RCTs, n=130, WMD: -1.52 (95%CI: -3.24, 0.20), *p*=0.08; *I^2^*=0%, [Figure 2](#fig002){ref-type="fig"}) when compared to the control group although the improvement did not reach a significant level. The results remained after removing two trials (Shamir 2001 and Zhu 2010) with non-normal distributions data (WMD: -2.70 (95%CI: -6.58,1.19, *p*=0.17; *I^2^*=0%). Due to the limited number of RCTs, risk of publication bias could not be examined. The overall evidence quality of the improvement of TD symptoms was rated as "Low" ([table 3](#table003){ref-type="table"}).

3.8 Secondary outcomes {#sec2-12}
----------------------

Cognitive function: One RCT (Zhu 2010) assessed the cognitive effects of the melatonin treatment ([Table 4](#table004){ref-type="table"}). Adjunctive melatonin outperformed the control group in the Wechsler Adult Intelligence Scale-Revised, Chinese version (WAIS-RC) \[including verbal scale, performance scale and full scale total scores\], Verbal Fluency Test (VFT) \[including animal, fruit, and word and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) \[including verbal fluency\]. In terms of cognitive function assessed by the Wechsler Memory Scale (WMS), no difference was found between the two groups (total score and memory quotient of WMS).

ADRs: Only one RCT (Zhu 2010) assessed ADRs using the Treatment Emergent Symptom Scale (TESS), and no group difference was found ([Table 4](#table004){ref-type="table"}).

Discontinuation rate: Regarding discontinuation rate, one RCT (Shamir 2001) reported that 2 patients were discharged before the randomization.

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-13}
-----------------

Previously only one review^\[[@ref5]\]^ with 2 RCTs (n=41) involved the therapeutic effects and safety of adjunctive melatonin for schizophrenia patients suffering from TD, finding an advantage of melatonin in improving the severity of TD symptoms. In this meta-analysis (4 RCTs, n=130) based on English and Chinese databases, the results showed that adjunctive melatonin outperformed the control group in treating the severity of TD symptoms although the improvement did not reach significance level. The strengths of this meta-analysis are the inclusion of two additional RCTs^\[[@ref6],[@ref9]\]^ and the inclusion of Chinese databases with low quality. In addition, quality assessment of included studies using the Cochrane risk of bias^\[[@ref27]\]^ and Jadad scale^\[[@ref28]\]^ were conducted. The overall quality level of primary outcome were rated as "Low" using the GRADE approach. However, the data on the ADRs and cognitive effect were only reported in one RCT (Zhu 2010), which limits our capacity to conduct meta-analysis.

Possible mechanism of melatonin in improving TD could be due to its potent antioxidant properties, which reduces oxidative stress, enhances BDNF levels and decreases the chance of neurotoxicity.^\[[@ref5]\]^ Furthermore, Zisapel's study^\[[@ref31]\]^ suggested that melatonin inhibits dopamine release in specific areas of the mammalian central nervous system (including retina, hypothalamus, medulla-pons, and hippocampus). Thus, melatonin could modulate dopaminergic pathways associated with movement disorders including TD.

4.2 Limitations {#sec2-14}
---------------

First, the sample sizes were relatively small and some information was limited, which failed to bring about a robust result.^\[[@ref32]\]^ Second, the dose-response effect of adjunctive melatonin (2 to 20mg/day) on TD symptoms could not be evaluated. Third, since all included RCTs were of short duration, ranging from 4 to 12 weeks, the long-term effects of melatonin on TD need to be examined further. Finally, we made a minor correction in the methods and made it differ from the protocol of this meta-analysis, i.e., "only randomized double blinded controlled trials were included" was changed to "only randomized controlled trials were included".

4.3 Implications {#sec2-15}
----------------

TD is irreversible, severe, and disabling, and so far no therapeutic strategies have been approved by the Food and Drug Administration (FDA). One meta-analysis of adjunctive EGb (ginkgo)^\[[@ref4]\]^ including 3 RCTs found adjunctive EGb could significantly reduce the severity of TD symptoms in schizophrenia. Another meta-analysis found that while adjunctive vitamin E^\[[@ref15]\]^ was similar with placebo in improving TD symptoms, it could significantly slow down the progression of the severity of TD symptoms in schizophrenia. Moreover, the previous systematic review^\[[@ref5]\]^ has explored the therapeutic effects of adjunctive melatonin, piracetam, and vitamin B6 on TD in schizophrenia. If melatonin is shown to be effective in TD, it may be a readily accessible and affordable option. However, future higher quality and larger RCTs are needed to confirm these results.

4.4 Conclusion {#sec2-16}
--------------

This meta-analysis shows that melatonin has potential for improving TD symptoms in schizophrenia. However, higher quality and larger RCTs are needed to confirm these findings, especially focusing on long-term therapeutic effects.
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###### 

Characteristics of the included studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  study (Country)                        N    Design:\                                                                                               Participants:\             Age^[a](#tfn001){ref-type="table-fn"}^:\   Sex^[a](#tfn001){ref-type="table-fn"}^:\   Interventions:\                                                                                                                                                                                                                 -Trial Duration (wks)\                   Jadad score
                                              -Blinding\                                                                                             -Diagnosis\                yrs\                                       Male\                                      -Mean dose (mg/day)\                                                                                                                                                                                                            -Outcomes                                
                                              -Setting                                                                                               -Criteria\                 (range)                                    (%)                                        -Range (mg/day)\                                                                                                                                                                                                                                                         
                                                                                                                                                     -Illness duration                                                                                                -Number of patients                                                                                                                                                                                                                                                      
  -------------------------------------- ---- ------------------------------------------------------------------------------------------------------ -------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------- -------------
  Castro 2011^\[[@ref9]\]^ (Venezuela)   13   -Double blind -Inpatients (15%) and outpatient settings (23%) and a rehabilitation institution (62%)   -TD -DSM-IV-TR -30.9 yrs   59.9 (46-75)                               n=9 (69.2%)                                APs^[b](#tfn002){ref-type="table-fn"}^ (M=400^[c](#tfn003){ref-type="table-fn"}^) + MEL (20^[c](#tfn003){ref-type="table-fn"}^); n=7 APs^[b](#tfn002){ref-type="table-fn"}^ (M=400^[c](#tfn003){ref-type="table-fn"}^); n=6     -12 -AIMS                                4

  Shamir 2000^\[[@ref10]\]^ (Israel)     19   -Double blind (crossover)^[d](#tfn004){ref-type="table-fn"}^ -Inpatients (100%)                        -TD -DSM-IV -31.3 yrs      74.0 (55-91)                               n=8 (42.1%)                                APs^[e](#tfn005){ref-type="table-fn"}^ (M=238^[c](#tfn003){ref-type="table-fn"}^) + MEL(2^[c](#tfn003){ref-type="table-fn"}^); n=9 APs^[e](#tfn005){ref-type="table-fn"}^ (M=238^[c](#tfn003){ref-type="table-fn"}^); n=10      -4 -AIMS                                 4

  Shamir 2001^\[[@ref11]\]^ (Israel)     22   -Double blind (crossover)^[c](#tfn003){ref-type="table-fn"}^ -Inpatients (100%)                        -TD -DSM-IV -24.8 yrs      64.2 (28-82)                               n=11 (50.0%)                               APs^[f](#tfn006){ref-type="table-fn"}^ (M=202^[c](#tfn003){ref-type="table-fn"}^) + MEL (10^[c](#tfn003){ref-type="table-fn"}^); n=12 APs^[f](#tfn006){ref-type="table-fn"}^ (M=202^[c](#tfn003){ref-type="table-fn"}^); n=10   -6 -AIMS                                 5

  Zhu 2010^\[[@ref6]\]^ (China)          76   -Single blind -Inpatients (100%)                                                                       -TD -CCMD-3 NA             57.6 (NA)                                  n=26 (34.2%)                               APs^[g](#tfn007){ref-type="table-fn"}^ (M=NA) + MEL (9^[c](#tfn003){ref-type="table-fn"}^); n=39 APs^[g](#tfn007){ref-type="table-fn"}^ (M=NA); n=37                                                                            -12 -AIMS; TESS; WAIS; WMS; VFT; RBANS   1
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Mean baseline.

^b^Including levopromazine, haloperidol, clozapine, aripiprazole, olanzapine, quetiapine and risperidone.

^c^Mean dose of APs (in chlorpromazine equivalents) or fixed dosage of MEL.

^d^We only extracted data from the first phrase.

^e^Including haloperidol, perphenazine and zuclopenthixol.

^f^Including haloperidol, perphenazine, zuclopenthixol and chlorpromazine.

^g^Failed to report detailed use of antipsychotics.

APs=antipsychotics; AIMS=Abnormal Involuntary Movement of Scale; CCMD-3=China's Mental Disorder Classification and Diagnosis Standard 3^th^ edition; CPZ-equ= chlorpromazine equivalents; DSM-IV=Diagnostic and Statistical Manual of Mental Disorders 4^th^ edition; DSM-IV-TR=Diagnostic and Statistical Manual of Mental Disorders, 4^th^ Edition, Text Revision; M=mean; MEL=melatonin; NA=not available; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; TESS=Treatment Emergent Symptom Scale; VFT=Verbal fluency test; yrs=years; WAIS=Wechsler Adult Intelligence Scale; WMS=Wechsler Memory Scale; wks=Weeks.

###### 

Evaluation of risk of bias in the included studies

  study                        sequence generation   allocation sequence concealment   blinding of participants and personnel   blinding of outcome assessment   incomplete outcome data   selective outcome reporting   other potential threats to validity
  ---------------------------- --------------------- --------------------------------- ---------------------------------------- -------------------------------- ------------------------- ----------------------------- -------------------------------------
  Castro 2011^\[[@ref9]\]^     N/A                   N/A                               low                                      low                              low                       N/A                           N/A
  Shamir 2000 ^\[[@ref10]\]^   N/A                   low                               low                                      low                              low                       low                           N/A
  Shamir 2001^\[[@ref11]\]^    low                   low                               low                                      low                              low                       low                           N/A
  Zhu 2010^\[[@ref6]\]^        high                  N/A                               high                                     low                              low                       N/A                           N/A

N/A=no information available

###### 

Adjunctive Melatonin for Tardive Dyskinesia: GRADE assessments

  Outcomes        number of studies (pooled sample)   test for heterogeneity   Analytic model   test for overall effect   estimate   95%confidence interval of estimate   GRADE                        
  --------------- ----------------------------------- ------------------------ ---------------- ------------------------- ---------- ------------------------------------ ------------ --------------- -----
  Effectiveness   4(130)                              0%                       0.89             random                    1.73       0.08                                 -1.52(WMD)   -3.24 to 0.20   Low

GRADE=Grades of Recommendation, Assessment, Development, and Evaluation; WMD=weighted mean difference

###### 

Adjunctive Melatonin for Tardive Dyskinesia: Cognitive Function at endpoint and ADRs

  Secondary outcomes       Studies    Scale of assessment        Findings
  ------------------------ ---------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Cognitive function**   Zhu 2010   WAIS-RC; WMS; VFT; RBANS   Adjunctive melatonin outperformed the control group in the WAIS-RC (including verbal scale, performance scale and full scale total scores), VFT (including animal, fruit, and word) and RBANS (including verbal fluency). No significant effects for other domains (including total score and memory quotient of WMS).
  **ADRs**                 Zhu 2010   TESS                       Not significant

ADRs=adverse drug reactions; RBANS=Repeatable Battery for the Assessment of Neuropsychological Status; TESS=Treatment Emergent Symptom Scale; VFT=Verbal Fluency Test; WAIS-RC= Wechsler Adult Intelligence Scale-Revise, Chinese version; WMS=Wechsler Memory Scale.
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